Santoni, Natália, Thaís Melo, Anna Rita Aguirre, Daniela Veiga, e Camila Souza. “Cost-Effectiveness of Afatinib Versus Pemetrexed Plus Cisplatin, Erlotinib and Gefitinib As First Line Treatment in Patients With Locally Advanced or Metastatic Epidermal Growth Factor Receptor Mutation (EFGR+) Non-Small Cell Lung Cancer in the Brazil”. Jornal Brasileiro de Economia da Saúde 9, no. 1 (abril 20, 2017): 73–82. Acessado abril 23, 2026. https://www.jbes.com.br/index.php/jbes/article/view/295.